Biomed plans to conduct two Phase 3 clinical trials programs for NA-831:
(1) COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.
(2) PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.
These trials follow strict scientific standards and regulatory requirements to protect patients and produce reliable results.
Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.
The Phase 3 clinical trials have been designed to evaluate safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
Please contact us for study locations near you. Contact information is provided so you can reach out to them to find out more and schedule a visit.
For further information about our products, please contact us. Contact us